Diagnosed Breast Cancer Population in China Will Increase Substantially Through 2011

Roche's Herceptin Will Experience Higher Penetration into the Treatment-

Eligible Population in China, According to a New Report from Decision

Resources

    WALTHAM, Mass., June 25 /PRNewswire/ -- Decision Resources, one of the
 world's leading research and advisory firms focusing on pharmaceutical and
 healthcare issues, forecasts that the diagnosed breast cancer population in
 China will increase substantially. According to the new Emerging Markets
 report entitled Breast Cancer in China, a rapidly aging population will be
 a key driving force behind an increase of almost 25% in the breast cancer
 diagnosed incident population between 2006 and 2011 in China, as average
 life expectancy rises and deaths from infectious diseases fall.
 Additionally, sustained migration from rural to urban China during recent
 decades has exposed more individuals to risk factors for breast cancer that
 are associated with urbanization.
     "The diagnosed incident breast cancer population in China will
 increasingly be distributed toward urban areas, where a growing number of
 residents continue to adopt nutritional patterns and sedentary lifestyles
 typical of Western countries," said Ramya Kollipara, Ph.D., analyst at
 Decision Resources. "The burden of disease will grow disproportionately in
 cities as a result of urbanization."
     The report also finds that Roche's Herceptin will experience higher
 penetration in the treatment-eligible population in China, and sales of
 this agent will increase rapidly between 2006 and 2011. Clinicians are
 becoming more familiar with this agent, which has shown better efficacy and
 toxicity profiles in Chinese patients than the market-leading small
 molecules.
     About Emerging Markets - China
     Emerging Markets - China is the first and only syndicated report series
 focusing on a high-growth emerging market with comprehensive
 disease-specific analysis. With these reports, biopharmaceutical companies
 can accomplish the following:
     -- More accurately assess their commercial opportunity for Western brands
        in key pharmaceutical markets of China - Beijing, Shanghai, Guangzhou -
        and in the high-growth second-tier markets of Tianjin, Wuhan, Nanjing,
        Hangzhou, and Jinan.
     -- Understand the physician treatment patterns and drivers of choice in
        key first- and second-tier cities based on primary research.
     -- Gain a clear perspective of the Chinese five-year market forecast at
        the drug level, broken out by urban and rural areas, and by sales from
        multinational and Chinese-based companies.
     About Decision Resources
     Decision Resources, Inc., (www.DecisionResources.com) is a world leader
 in healthcare market research publications, advisory services, and
 consulting designed to help clients shape strategy, allocate resources, and
 master their chosen markets.
     All company, brand, or product names contained in this document may be
 trademarks or registered trademarks of their respective holders.
     For more information, contact:
 
     Elizabeth Marshall
     Decision Resources, Inc.
     781-296-2563
     emarshall@dresources.com
 
 

SOURCE Decision Resources